Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Retained Earnings (2019 - 2026)

Enliven Therapeutics has reported Retained Earnings over the past 8 years, most recently at -$382000.0 for Q1 2026.

  • Quarterly results put Retained Earnings at -$382000.0 for Q1 2026, down 2287.5% from a year ago — trailing twelve months through Mar 2026 was -$382000.0 (down 2287.5% YoY), and the annual figure for FY2025 was -$347.2 million, down 631310.91%.
  • Retained Earnings reached -$382000.0 in Q1 2026 per ELVN's latest filing, up from -$347.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $141000.0 in Q4 2023 and bottomed at -$347.2 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$114.3 million (2023), compared with a mean of -$126.2 million.
  • Peak annual rise in Retained Earnings hit 100.17% in 2023, while the deepest fall reached 3377400.0% in 2023.
  • Over 5 years, Retained Earnings stood at -$82.9 million in 2022, then soared by 100.17% to $141000.0 in 2023, then plummeted by 60.99% to $55000.0 in 2024, then plummeted by 631310.91% to -$347.2 million in 2025, then skyrocketed by 99.89% to -$382000.0 in 2026.
  • Business Quant data shows Retained Earnings for ELVN at -$382000.0 in Q1 2026, -$347.2 million in Q4 2025, and -$317.5 million in Q3 2025.